| | |
I.v/single p.o (pen V,G) (n = 21)**
|
P.o.7 (pen V) (n = 15)*
|
Single p.o (other) (n = 8)*
|
P.o.7 (other) (n = 8)*
|
|---|
| | |
Pos (n = 2)
|
Neg (n = 19)
|
Pos (n = 2)
|
Neg (n = 13)
|
Pos (n = 1)
|
Neg (n = 7)
|
Pos (n = 1)
|
Neg (n = 7)
|
|---|
|
Post-challenge s-IgE
|
Pos (n = 11)
|
1
|
3
|
1
|
5
|
1**
|
0
|
0
|
0
|
| |
Neg (n = 25)
|
1
|
11*
|
1
|
4
|
0
|
4
|
1
|
4*
|
| |
NT (n = 12)
|
0
|
5
|
0
|
4
|
0
|
3
|
0
|
3
|
- A total of 21 patients were challenged with i.v/single p.o pen V, followed by p.o.7 pen V in 15 patients. **Patient no. 5 (Table 1) was only challenged with culprit drug (DX).
- Nine patients also challenged with other drug (either their culprit drug or because of previous positive specific IgE to AMP or AX). In 8 cases initiated by single p.o, and in 1 case* (no. 17, Table 1) initiated by challenge with pen G and V (i.v/single p.o), followed by challenge with AX (culprit drug) in p.o.7 (not preceded by single p.o AX). No. 17, Table 1 had not performed p.o.7 with pen V.
- s-IgE: serum specific IgE to penicillin, I.v: intravenous, Single p.o: single dose oral challenge, P.o.7: 7-day oral challenge, Pen V: phenoxymethylpenicillin, Pen G: benzylpenicillin, DX: dicloxacillin, AX: amocxicillin, Pos: positive, Neg: negative, NT: not tested.
